anticoagulation

Bivalirudin (BG-8967) is a reversible inhibitor of α- and ζ-thrombin (Kis = 2.56 and 1.84 nM, respectively), enzymes that exhibit high fibrinogen-clotting activities.

(R)-Acenocoumarol ((R)-Acenocoumarin; (R)-Nicoumalone) is a short-acting, orally administered anticoagulant that works by inhibiting vitamin K epoxide reductase (vitamin K1 recycling), similar to Warfarin. It demonstrates greater anticoagulant potency in vivo compared to Warfarin. This compound has a single chiral center, resulting in two enantiomeric forms. The (R)-enantiomer has a longer plasma elimination half-life of 6.6 hours, slower plasma clearance of 1.9 L/h, and stronger anticoagulation effects than the (S)-enantiomer.

Anivamersen is an RNA aptamer designed to reverse the effects of the parenteral factor IXa inhibitor pegnivacogin. REG1, a novel anticoagulation system, comprises pegnivacogin (an RNA aptamer inhibitor of coagulation factor IXa) and anivamersen (a complementary sequence reversal oligonucleotide).

Anivamersen sodium, a complementary sequence reversal oligonucleotide, serves as an RNA aptamer designed to reverse the anticoagulant effect of the parenteral factor IXa inhibitor pegnivacogin. Together, pegnivacogin—a coagulation factor IXa inhibiting RNA aptamer—and anivamersen comprise REG1, a novel anticoagulation system.

Protodeltonin may have anti-thrombotic activity by both improving the anticoagulation activity and inhibiting platelet aggregation action. Protodeltonin can inhibit the proliferation of a panel of established human and murine cancer cell lines in vitro.